Achieve Life Sciences (ACHV) Consolidated Net Income (2010 - 2018)
Achieve Life Sciences (ACHV) recorded quarterly Consolidated Net Income of -$3.6 million in Q4 2018, down 12.25% on a QoQ basis from -$3.2 million in Q3 2018, and up 2.75% year-over-year from -$3.5 million in Q4 2017.
Achieve Life Sciences (ACHV) Consolidated Net Income (2010 - 2018) Analysis & Trends
Achieve Life Sciences has disclosed Consolidated Net Income across 7 years of filings, most recently posting -$3.6 million for Q4 2018.
- Quarterly Consolidated Net Income rose 2.75% year-over-year to -$3.6 million in Q4 2018, while the trailing twelve-month figure through Sep 2019 was -$3.6 million (up 71.56% YoY) and the FY2019 annual result came in at -$16.4 million, down 29.23% from the prior year.
- Consolidated Net Income eased to -$3.6 million in Q4 2018, from -$3.2 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$166000.0 in Q2 2017 and troughed at -$9.4 million in Q3 2017.
- A 4-year average of -$2.6 million and a median of -$2.8 million in 2018 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2017 — Consolidated Net Income sank 2220.99% — and 2018, when it soared 65.53%.
- Tracing ACHV's Consolidated Net Income over 4 years: stood at -$1.2 million in 2015, then jumped by 50.36% to -$613000.0 in 2016, then slumped by 510.11% to -$3.7 million in 2017, then advanced by 2.75% to -$3.6 million in 2018.
- Business Quant data shows ACHV's Consolidated Net Income at -$3.6 million in Q4 2018, -$3.2 million in Q3 2018, and -$2.8 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -3.64 Mn |
| Sep 30, 2018 | -3.24 Mn |
| Jun 30, 2018 | -2.79 Mn |
| Mar 31, 2018 | -3.02 Mn |
| Dec 31, 2017 | -3.74 Mn |
| Sep 30, 2017 | -9.40 Mn |
| Jun 30, 2017 | -166,000.00 |
| Mar 31, 2017 | -329,000.00 |
| Dec 31, 2016 | -613,000.00 |
| Sep 30, 2016 | -405,000.00 |
| Dec 31, 2015 | -1.24 Mn |
| Dec 31, 2012 | -38.09 Mn |
| Sep 30, 2012 | 5.92 Mn |
| Jun 30, 2012 | 4.22 Mn |
| Mar 31, 2012 | -6.86 Mn |
| Dec 31, 2011 | -19.78 Mn |
| Sep 30, 2011 | -4.47 Mn |
| Jun 30, 2011 | 6.53 Mn |
| Mar 31, 2011 | -3.05 Mn |
| Dec 31, 2010 | -2.80 Mn |